Taysha Gene Therapies (id:8424 TSHA)

2.47 USD

Opening hours: 09:30 - 16:00 (Eastern Standard Time: 11/24/2024 9:14:49 PM)

Exchange closed, opens in 12 hours 15 minutes

• 1 day
• 1 week
• 1 month
• 6 months
• 1 year
• All

About Taysha Gene Therapies

Market Capitalization 411.94M

Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.